JAGX vs. NERV, PHXM, HCWB, DWTX, LSB, APRE, PHIO, TLPH, CYCN, and ORGS
Should you be buying Jaguar Health stock or one of its competitors? The main competitors of Jaguar Health include Minerva Neurosciences (NERV), PHAXIAM Therapeutics (PHXM), HCW Biologics (HCWB), Dogwood Therapeutics (DWTX), Lakeshore Biopharma (LSB), Aprea Therapeutics (APRE), Phio Pharmaceuticals (PHIO), Talphera (TLPH), Cyclerion Therapeutics (CYCN), and Orgenesis (ORGS). These companies are all part of the "pharmaceutical products" industry.
Jaguar Health vs. Its Competitors
Jaguar Health (NASDAQ:JAGX) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, community ranking, valuation and risk.
In the previous week, Jaguar Health and Jaguar Health both had 1 articles in the media. Minerva Neurosciences' average media sentiment score of 0.94 beat Jaguar Health's score of 0.31 indicating that Minerva Neurosciences is being referred to more favorably in the news media.
Jaguar Health has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, Minerva Neurosciences has a beta of -0.37, meaning that its stock price is 137% less volatile than the S&P 500.
Jaguar Health received 1489 more outperform votes than Minerva Neurosciences when rated by MarketBeat users. Likewise, 88.57% of users gave Jaguar Health an outperform vote while only 55.52% of users gave Minerva Neurosciences an outperform vote.
Minerva Neurosciences has a net margin of 0.00% compared to Jaguar Health's net margin of -360.13%. Minerva Neurosciences' return on equity of 0.00% beat Jaguar Health's return on equity.
Jaguar Health presently has a consensus target price of $60.00, suggesting a potential upside of 1,466.58%. Minerva Neurosciences has a consensus target price of $5.00, suggesting a potential upside of 180.11%. Given Jaguar Health's stronger consensus rating and higher possible upside, analysts plainly believe Jaguar Health is more favorable than Minerva Neurosciences.
Minerva Neurosciences has lower revenue, but higher earnings than Jaguar Health.
12.0% of Jaguar Health shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 0.4% of Jaguar Health shares are held by insiders. Comparatively, 8.6% of Minerva Neurosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Jaguar Health and Minerva Neurosciences tied by winning 7 of the 14 factors compared between the two stocks.
Get Jaguar Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for JAGX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding JAGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Jaguar Health Competitors List
Related Companies and Tools
This page (NASDAQ:JAGX) was last updated on 6/13/2025 by MarketBeat.com Staff
Buy JAGX Stock Free JAGX Stock Alerts